| 99.06 0.71 (0.72%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 116.2 | 1-year : | 135.72 |
| Resists | First : | 99.48 | Second : | 116.2 |
| Pivot price | 95.11 |
|||
| Supports | First : | 95.07 | Second : | 92.34 |
| MAs | MA(5) : | 96.83 |
MA(20) : | 95.25 |
| MA(100) : | 100.27 |
MA(250) : | 99.9  |
|
| MACD | MACD : | -0.3 |
Signal : | -1 |
| %K %D | K(14,3) : | 82.3 |
D(3) : | 66.4 |
| RSI | RSI(14): 61.9 |
|||
| 52-week | High : | 108.77 | Low : | 92.19 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ NVS ] has closed Bollinger Bands are 9.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 99.3 - 99.59 | 99.59 - 99.92 |
| Low: | 97.35 - 97.72 | 97.72 - 98.13 |
| Close: | 98.42 - 98.97 | 98.97 - 99.58 |
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Wed, 24 Apr 2024
Q3 2025 EPS Estimates for Novartis AG (NYSE:NVS) Cut by Zacks Research - MarketBeat
Wed, 24 Apr 2024
Novartis AG (NYSE:NVS) Q1 2024 Earnings Call Transcript - Yahoo Finance
Tue, 23 Apr 2024
Why Novartis Stock Topped the Market on Tuesday - The Motley Fool
Tue, 23 Apr 2024
FY2026 EPS Estimates for Novartis AG (NYSE:NVS) Lifted by Analyst - MarketBeat
Tue, 23 Apr 2024
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript - The Motley Fool
Tue, 23 Apr 2024
Novartis: Q1 Earnings Snapshot - Darien Times
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,040 (M) |
| Shares Float | 1,960 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 6.9 (%) |
| Shares Short | 4,210 (K) |
| Shares Short P.Month | 4,530 (K) |
| EPS | 4.09 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.82 |
| Profit Margin | 31.8 % |
| Operating Margin | 25.3 % |
| Return on Assets (ttm) | 7.2 % |
| Return on Equity (ttm) | 16.1 % |
| Qtrly Rev. Growth | 7.4 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 22.87 |
| EBITDA (p.s.) | 8.58 |
| Qtrly Earnings Growth | 498.7 % |
| Operating Cash Flow | 14,460 (M) |
| Levered Free Cash Flow | 12,130 (M) |
| PE Ratio | 24.16 |
| PEG Ratio | 1.9 |
| Price to Book value | 4.33 |
| Price to Sales | 4.33 |
| Price to Cash Flow | 13.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|